

## Technology Appraisal Committee B Interests Register

**Topic: Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]**

**Publication Date: 13 August 2025**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David McAllister	Committee Member	Non-Financial Professional	David has received individual-level clinical trial data from competitor organisations via the Vivli repository.	04/06/2025 08/05/2025	It was agreed that David's declaration would not prevent him from participating in the committee meeting.
Wallace Brownlee	Clinical Expert	Direct Financial	Mr Brownlee has received honoraria for participation in educational activities and/or consulting from Biogen, Merck, Neuraxpharm, Novartis, Roche, Sanofi, Sandoz and Viartis	04/06/2025	It was agreed that Mr Brownlee's declaration would not prevent him from providing expert advice to the committee.
Ruth Dobson	Clinical Expert	Direct Financial	Professor Dobson has not received personal direct payments for speaking, consultancy or advisory board membership. All honoraria for such work have been made directly to her institution and used to support education and research for other members of her research group. She does not perform any private practice.	04/06/2025	It was agreed that Professor Dobson's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David McAllister	Committee Member	Non-Financial Professional	David has received individual-level clinical trial data from competitor organisations via the Vivli repository.	04/06/2025 08/05/2025	It was agreed that David's declaration would not prevent him from participating in the committee meeting.
		Direct – non-financial	<p>Professor Dobson's current role as Professor of Neurology could be seen as a direct interest according to the NICE DoI policy. She is currently chair of the ABN AG for MS and neuroinflammation (member 2021 – 2024, Chair 2024 – present). She is currently a member of NHSE Neurology CRG. She has authored publications including ABN guidelines on DMT use in MS and ABN guidelines on the treatment of MS in Pregnancy.</p> <p>Professor Dobson's institution has previously received research funding from Biogen for research led by her (2021-2022). Professor Dobson's institution currently receives research funding from Imperial College for a project funded by Biogen (2018-present). Professor</p>		It was agreed that Professor Dobson's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David McAllister	Committee Member	Non-Financial Professional	David has received individual-level clinical trial data from competitor organisations via the Vivli repository.	04/06/2025 08/05/2025	It was agreed that David's declaration would not prevent him from participating in the committee meeting.
			<p>Dobson's institution has received compensation for my time from Sandoz (2023-2024) and Biogen (2022).</p> <p>Professor Dobson's institution has previously received research funding from Merck for research led by her (2021-2022). Professor Dobson's institution currently receives research funding from Imperial College for a project funded by Merck (2018-present), previously additionally funded by Celgene (2019-2021). My institution has received compensation for my time from Janssen (2020-2022), Novartis (2022), Roche (2022-2024), and Merck (2019).</p> <p>She is currently a PI on a clinical trial sponsored by Roche (2021-</p>		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David McAllister	Committee Member	Non-Financial Professional	David has received individual-level clinical trial data from competitor organisations via the Vivli repository.	04/06/2025 08/05/2025	It was agreed that David's declaration would not prevent him from participating in the committee meeting.
			present) for which her institution receives support.		
Emily Reves	Patient Expert	Indirect - Financial	MS Society funding - Merck Serono May 2024 - Grant towards Helpline Specialist Nurses service - £20,000.  Roche - Feb 2024 - Sponsorship of MS Frontiers conference - £10,000, May 2024 - Grant towards the MS Helpline - £35,000.  Sanofi Genzyme - June 2024 - sponsorship of MS Frontiers conference - £10,000.	08/05/2025	It was agreed that Ms Reves's declaration would not prevent her from providing expert advice to the committee.